Emerging Diabetes Therapies: Regenerating Pancreatic β Cells
Tissue Engineering Part B: Reviews · 01.12.2024 · 30 (6) · 644-656
DOI: 10.1089/ten.teb.2024.0041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tissue Engineering Part B: Reviews, erschienen am 01.12.2024. Verfasst von Haojie Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Insulin-Secreting Cells, Regeneration. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The incidence of diabetes mellitus (DM) is steadily increasing annually, with 537 million diabetic patients as of 2021. Restoring diminished β cell mass or impaired islet function is crucial in treating DM, particularly type 1 DM. However, the regenerative capacity of islet β cells, which primarily produce insulin, is severely limited, and natural regeneration is only observed in young rodents or children. Hence, there is an urgent need to develop advanced therapeutic approaches that can regenerate endogenous β cells or replace them with stem cell (SC)-derived or engineered β-like cells. Current strategies for treating insulin-dependent DM mainly include promoting the self-replication of endogenous β cells, inducing SC differentiation, reprogramming non-β cells into β-like cells, and generating pancreatic-like organoids through cell-based intervention. In this Review, we discuss the current state of the art in these approaches, describe associated challenges, propose potential solutions, and highlight ongoing efforts to optimize β cell or islet transplantation and related clinical trials. These effective cell-based therapies will generate a sustainable source of functional β cells for transplantation and lay strong foundations for future curative treatments for DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Receptors-Mediated Gene Regulation and Drug Discovery, School of Basic Medical Sciences, Henan University, Kaifeng, China.
- Kaifeng 155 Hospital, China RongTong Medical Healthcare Group Co. Ltd., Kaifeng, China.
- Department of Urinary Surgery, Henan Provincial Research Center for the Prevention and Diagnosis of Prostate Diseases, Huaihe Hospital, Henan University, Kaifeng, China.
ORCID-Profile: Xiaobo Nie
Zitieren
APA
Zhang, H., Wei, Y., Wang, Y., Liang, J., Hou, Y., Nie, X., & Hou, J. (2024). Emerging Diabetes Therapies: Regenerating Pancreatic β Cells. Tissue Engineering Part B: Reviews, 30(6), 644-656. https://doi.org/10.1089/ten.teb.2024.0041
Vancouver
Zhang H, Wei Y, Wang Y, Liang J, Hou Y, Nie X, et al. Emerging Diabetes Therapies: Regenerating Pancreatic β Cells. Tissue Engineering Part B: Reviews. 2024;30(6):644-656. doi:10.1089/ten.teb.2024.0041
BibTeX
@article{Zhang2024,
author = {Zhang, Haojie and Wei, Yaxin and Wang, Yubo and Liang, Jialin and Hou, Yifan and Nie, Xiaobo and Hou, Junqing},
title = {Emerging Diabetes Therapies: Regenerating Pancreatic β Cells},
journal = {Tissue Engineering Part B: Reviews},
year = {2024},
volume = {30},
number = {6},
pages = {644--656},
doi = {10.1089/ten.teb.2024.0041}
}
EUVIMED